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ABSTRACT
The severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) pandemic will be remembered as one
of the defining events of the 21st century. The rapid
global outbreak has had significant impacts on hu-
man society and is already responsible for millions
of deaths. Understanding and tackling the impact of
the virus has required a worldwide mobilisation and
coordination of scientific research. The COVID-19
Data Portal (https://www.covid19dataportal.org/) was
first released as part of the European COVID-19 Data
Platform, on April 20th 2020 to facilitate rapid and
open data sharing and analysis, to accelerate global
SARS-CoV-2 and COVID-19 research. The COVID-19
Data Portal has fortnightly feature releases to con-
tinue to add new data types, search options, visual-
isations and improvements based on user feedback
and research. The open datasets and intuitive suite
of search, identification and download services, rep-
resent a truly FAIR (Findable, Accessible, Interopera-
ble and Reusable) resource that enables researchers
to easily identify and quickly obtain the key datasets
needed for their COVID-19 research.
GRAPHICAL ABSTRACT
INTRODUCTION
The COVID-19 Data Portal (CDP; https://www.
covid19dataportal.org/) aims to accelerate global SARS-
CoV-2 research through rapid open access data sharing
(see Figure 1). The CDP forms part of the larger European
COVID-19 Data Platform (1) that also comprises the
SARS-CoV-2 Data Hubs and the Federated European
Genome-Phenome Archive (EGA) (2). The CDP is de-
veloped by a task force from the European Molecular
Biology Laboratory’s European Bioinformatics Institute
(EMBL-EBI; https://www.ebi.ac.uk/).
The CDP provides coverage of both SARS-CoV-2 virus –
in particular its ∼30 kb RNA genome and 29 genes (https://
cen.acs.org/biological-chemistry/infectious-disease/know-
novel-coronaviruss-29-proteins/98/web/2020/04)––and its
human host. In addition, data are available for non-SARS-
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Figure 1. shows the home page of the https://www.covid19dataportal.org portal and results from a search for ACE2 on the Protein structures category on
the Proteins section.
CoV-2 coronaviruses and non-human hosts. The resource
spans biomolecular data, comprising experimental and
computational data types related to the genome, genes,
proteins of SARS-CoV-2, structural and biochemical
interactions, and literature available from EMBL-EBI and
ELIXIR (https://elixir-europe.org/) data resources.
DATASETS AND AVAILABILITY
The CDP consists of seven main data categories: viral se-
quences, host sequences, expression, proteins, biochemistry,
imaging and literature. Here, we describe the data types
available in each of these sections.
Viral sequences
From the early days of the COVID-19 pandemic, nu-
cleotide sequencing data has been deposited in the Eu-
ropean Nucleotide Archive (ENA; https://www.ebi.ac.
uk/ena/browser/home) (3). This has led to a surge in
raw and assembled nucleotide sequences (as depicted
in graphs on the statistics page of the CDP https:
//www.covid19dataportal.org/statistics), COVID-19 Data
Portal: https://www.covid19dataportal.org/statistics), ow-
ing in part to dedicated viral data mobilisation efforts.
The Viral sequences data category includes publicly shared
SARS-CoV-2 whole genomes (sequences), presenting meta-
data such as date of sample collection and geographic lo-
cation, which allows for the characterisation of these data
at the national and institutional levels. Alongside SARS-
CoV-2 genomes, raw sequencing reads have also been sub-
mitted, which correlate to sequenced SARS-CoV-2 biolog-
ical samples from human hosts from 41 countries across
the world. With early sharing of the SARS-CoV-2 refer-
ence genome, genes comprising the virus have been anno-
tated through Ensembl (4) and are available from the Gene
category. These are also available through the Ensembl
COVID-19 genome browser (https://covid-19.ensembl.org/
SARS cov 2/Info/Index). Variation within the SARS-CoV-
2 genome has been captured through variant calling of
Nextstrain and ENA data, processed with Ensembl and
available in the Variants category. Refinements on variation
calling and presentation are underway.
Host sequences
Access to sensitive, human raw sequencing and biomolec-
ular data, including data from COVID-19 patient and
research subject studies, shared with authorised access
through the EGA, are available under the Host sequences
section in the CDP. Authorised access to these datasets is
provided through Data Access Committees according to
established EGA processes. SARS-CoV-2 related genome-
wide association studies from the GWAS Catalogue (5) re-
side in this category and provide access to datasets from
studies looking into genetic variations in contexts such as
susceptibility and severity of COVID-19 and its spread.
Non-sensitive human raw sequencing data from blood and
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tissue cell studies containing SARS-CoV-2 are archived in
the ENA and available for download directly from the CDP.
In addition, raw sequencing data of other non-human host
species, for example from mouse studies, are also available
under the Host sequences section.
Expression
Under the Expression data category, expression datasets
and experiments for host genes and proteins involved in
human SARS-CoV-2 transmission and infection are made
available. These datasets are provided through the Expres-
sion Atlas (6) and the Proteomics Identifications Database
(PRIDE) (7). The Single Cell Expression Atlas provides cell
and cell type datasets with elevated expression. These in-
clude experiments in human and mouse tissues that include
time track and infection profiles.
Proteins
Protein sequences from UniProtKB (8) that represent hu-
man gene products with experimental evidence of interac-
tion with SARS-CoV-2 surface proteins, as well as with
potential compound targets and models, are accessible in
the Protein section of the Data Portal. Also found in this
section are protein structures from the PDBe-KB data re-
source (9) and PDBe (10) that highlight important struc-
tural features, including ligand binding sites and protein-
protein interaction residues important in the research and
development of vaccines and therapeutics against SARS-
CoV-2. Protein families from InterPro (11) include entries
that match any of the virus proteins and that help with
further identification and characterisation of protein vari-
ants. The Electron microscopy maps and images category
contains entries from The Electron Microscopy Databank
(12) and The Electron Microscopy Public Imaging Archive.
This includes data from EMPIAR (13) that provides access
to 3-D structural models of the S-protein trimer, which is
critical in the design of vaccines, and other virus proteins
that may have potential to serve as antigens or compound
targets.
Biochemistry
Biomolecular interactions, targets, compounds, complexes
and pathways implicated in COVID-19 comprise the Bio-
chemistry section of the portal. Biological pathways identi-
fied in SARS-CoV-2 host cell infection and replication from
Reactome (14) are available here, as well as molecular inter-
action data from user submissions and literature curation
from the IntAct Molecular Interaction Database (15). It
also provides access to macromolecular complexes from the
Complex Portal (16), the majority of which are protein com-
plexes involved in processes facilitating virus entry, replica-
tion and spread.
Furthermore, studies investigating compounds and their
effects on SARS-CoV-2 activity (for example studies re-
searching potential therapeutic targets), are available from
the Compound documents category, which presents data
from ChEMBL (17). Open Targets (18) provides evidence
of drug targets activity against COVID-19 on the Drug tar-
gets category. MetaboLights (19) entries relating to SARS-
CoV-2 infection and metabolic effects are available through
the Metabolomics experiments category.
Imaging
This section contains data from BioStudies (20) providing
data on compound screening and assays, as well as archived
microscopic images for SARS-CoV-2 studies. Electron mi-
croscopy imaging details data is also available through EM-
PIAR, characterising the virus structures and its infection
in various human tissues. These datasets are also accessible
through the Biochemistry section.
Literature
The CDP includes extensive automated literature detailing
SARS-CoV-2, COVID-19 and its effects, and related viruses
and diseases present through Europe PMC (21). The utilisa-
tion of prepublication resources, such as bioRxiv, have be-
come key for a rapid dissemination route for SARS-CoV-
2 research. Europe PMC has indexed these key prepubli-
cation COVID-19 manuscripts to ensure visibility in this
rapidly evolving field. The Literature section is solely ded-
icated to making these publications available to the user
community.
RELATED RESOURCES
Beyond the fine-grained biomolecular and literature access
available from the services described above, a number of fur-
ther biomolecular data and other resources are provided un-
der the Related resources section of the CDP. Here, top-level
information and links to relevant entry points are provided
to databases, tools and catalogues of relevance to COVID-
19. At the time of writing, 70 resources are linked.
DOCUMENTATION AND GUIDELINES
The CDP includes a number of pages providing information
on the European COVID-19 Data Platform as a whole, data
submission tools, data standards of relevance and partners
and funded projects involved in the Platform’s operations.
IMPORTANCE OF OPEN ACCESS DATA SHARING
Open science and open data are principles that are shared by
all EMBL-EBI and ELIXIR data resources and, from its in-
ception, the CDP has had the facilitation of open data shar-
ing as a core concept. It was recognised that unrestricted
access to data plays a critical role in the rapid coronavirus
research necessary to respond to this global health crisis.
This is crucial for the identification of drug targets, develop-
ing vaccines, understanding infection and symptoms, track-
ing the effects of new variants, and for policy makers de-
signing public health responses. Ensuring open science and
unrestricted international collaborations is of key impor-
tance, and it is recognised that these datasets must be shared
openly and meet FAIR standards (Findable, Accessible, In-
teroperable and Reusable).
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To this end, the CDP recently hosted an open letter
(https://www.covid19dataportal.org/support-data-sharing-
covid19) jointly calling upon the data submitters, data
users, policy makers and the wider research community,
to support truly open and unrestricted data sharing. At
the time of writing this letter has attracted 764 signatures.
The letter calls for submission of raw SARS-CoV-2 data
to the databases of the International Nucleotide Sequence
Database Collaboration (INSDC) (22). Authors ask
submitters to provide a key minimum set of information
relating to the sequenced isolate or sample as part of
the sequence submission, to maximise the value of the
sequences. Promoting open data sharing will also be key
for future pandemics, and to unleash the fast flow of
research advances into clinical use of sequencing for the
benefit of society.
COMPONENTS AND APIs
The CDP provides a categorised collection of related re-
sources including complementary databases, analysis tools,
data standards, related European projects and connections
to ELIXIR resources.
Searching and identifying relevant datasets for COVID-
19 research is one of the challenges the CDP meets head
on. EMBL-EBI has invested in the development and main-
tenance of a scalable text search engine, EBI Search (23),
that is currently indexing >3.7 billion records, comprising
the majority of data resources available from the institute.
The data in the CDP is obtained using the EBI Search API,
making use of its advanced search functionality. For virus
sequences, the EBI Search API and thus the CDP is capable
of querying genes, targets, sequencing technology, isolate or
strain names, submission centre names, country and pro-
tein products. The data retrieved can then be easily sorted
by submission or collection date.
Data obtained from the ENA is divided into data
type sections, denoting sequences, reference sequences, raw
reads, sample, studies, genes, browser assemblies and vari-
ants. These data can be searched, for example, by accession
number, date and date range, country, strains, isolates, hosts
and sequencing centre name. To help the user navigate these
data there are multi-selectable facets, for example, organ-
ism, first public date, collection date and sequencing centre
name.
Controlled-access human data come from serology anti-
body studies, immunoprofiling, paired-end sequencing and
genome wide genotyping. It is important to stress that these
data are in the public domain and have been anonymised by
the submitters. These data can be searched by study identi-
fier (for example, EGAS00001004412) or by using free text
descriptions.
Gene and protein expression experiments can be queried
by the gene name, organ or tissue and disease association.
Methods used to collect samples, such as nasal swabs, can
also be used to query, although they often appear as part
of free text fields in the data. Queries in these resources in-
clude expression accession numbers, gene names, Ensembl
identifiers and PRIDE experiment identifiers.
Protein data covers a broad set of queryable fields, includ-
ing biomolecular structure terms, protein family categories,
related organisms, authors, literature titles, dates and data
types. For example, the key COVID-19 protein sequences
for ACE2 Q9BYF1 or ACE2 HUMAN from UniProtKB;
the coronavirus S-protein IPR002551 from InterPro; the
spike receptor binding domain complex 6lzj from PDBe;
and the SARS-CoV-2 S trimer EMD-30701.
The key user queries that are possible in the Biochem-
istry section include the names of metabolic pathways re-
lated to the innate immune response of the host, maturation
of various proteins, translation and replication. The asso-
ciated compounds literature shows anti-coronavirus activ-
ity and drug targets with disease association scores, such as
cathepsin and metabolomic experiments showing response
to both drugs and infection. For example, MTBLS1987 de-
scribes the kynurenic acid sex-specific immune response in
COVID-19.
The CDP has a section dedicated to imaging data. At
present this comprises studies, such as high content screens
of cells treated with compound libraries. It also contains
assays for COVID-19 antibodies based on, for example,
high throughput microscopy, high resolution electron mi-
croscopy, movies of interaction in complexes and cryo-
electron microscopy.
Literature queries are possible that have authors, title and
publications divided into categories that distinguish results
based on criteria such as coronavirus, related viruses, gene,
receptor and antibodies, as well as other supplemental data.
Looking for further ways of improving the search and
retrieval capabilities of the CDP is always high on the
agenda and further feedback is most welcome. The CDP
readily accepts feature requests from the community it
supports through its inbuilt feedback pages of the CDP
mechanism. The CDP has a basic RESTful API page
that shows the relevant calls it makes to the various re-
sources, available here: https://www.covid19dataportal.org/
api-documentation. Any user can make use of these APIs
in a free and unrestricted manner as long as this is in accor-
dance with the EMBL-EBI General Terms of Use.
The CDP supports the direct download of all the se-
quences in a section, or up to 1000 selected sequences per
page. Due to the size of the sequencing datasets we also pro-
vide files containing the complete COVID-19 datasets via
FTP. For ease of download (particularly on slower inter-
net connections) the files have been split into chunks that
can be easily re-combined to form the complete dataset.
These files are available using the Aspera’s FASP (https:
//www.ibm.com/uk-en/products/aspera) file transfer proto-
col that is particularly effective for large downloads over less
stable internet connections. This is essential considering the
global importance of these datasets and the fact that many
researchers are not currently able to work on site at their
institutes, due to lockdown restrictions.
The CDP includes automatically generated statistics
(https://www.covid19dataportal.org/statistics) that are up-
dated as new data arrives. The charts track the growth of
SARS-CoV-2 viral sequences held in the CDP from differ-
ent countries, sequencing centres and contributing institu-
tions.
USAGE
Since its launch in April 2020, the CDP has been accessed
over 4 million times from 161 000 unique IP addresses from
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all over the world. At the time of writing, this translates
to approximately 70% usage from various Internet Service
Providers and the Data Centre hosting sector, which we be-
lieve reflects the various lockdowns and remote working
during 2020 and 2021. Eleven percent of all IPs are from
the commercial sector, including pharmaceutical compa-
nies, national and regional health centres and government
organisations, and 5% are from hosts in the education sec-
tor.
FUTURE WORK
The CDP has continued to evolve rapidly to meet the grow-
ing needs of the highly active global research community.
The CDP Task Force makes feature updates to the CDP
approximately every two weeks, announcing the feature
changes via the EMBL-EBI twitter account (@emblebi). In
addition to more data resources and data types being added
as COVID-19 annotations become available, plans to imple-
ment a cohort browser, genome assembly visualisation and
a host of other analyses and visualisations are in the current
roadmap.
DATA AVAILABILITY
All datasets supporting the CDP are available without re-
strictions from public data repositories.
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